Delving into dengue virus drug discovery- insights into the structural characteristics of the RNA-dependent RNA polymerase. by Ncube, Nomagugu Belinda.
  
 
 
Delving into Dengue Virus Drug Discovery- Insights into the 
Structural Characteristics of the RNA-Dependent RNA 
Polymerase. 
 
 
 
Miss Nomagugu B. Ncube 
2017 
 
 
 
 
A thesis submitted to the School of Health Sciences, University of KwaZulu 
Natal, Westville, in fulfilment for the degree of Master in Medical Sciences (Pharmaceutical 
Chemistry) 
 
  
 II 
Delving into Dengue Virus Drug Discovery- Insights into the Structural 
Characteristics of the RNA-Dependent RNA Polymerase. 
 
Miss Nomagugu B. Ncube 
2017 
 
 
 
A thesis submitted to the School of Pharmacy and Pharmacology, Faculty of Health Sciences, 
University of KwaZulu-Natal, Westville, for the degree of Master in Medical Sciences (Pharmaceutical 
Chemistry). 
 
This is the thesis in which the chapters are written as a set of discrete research publications, with an 
overall introduction and final summary. Typically, these chapters will have been published in 
internationally recognized, peer-reviewed journals.   
 
This is to certify that the contents of this thesis are the original research work of Miss N.B. Ncube. 
 
As the candidate’s supervisor, I have approved this thesis for submission.  
 
 
 
Supervisor: 
Signed:                                                                                                    Name: Prof Mahmoud Soliman  
Date: 29 November 2017 
 III 
ABSTRACT 
 
A precipitous increase in the number of flaviviral infections has been noted over the last five years. The 
present study sought to investigate a notorious flavivirus that has been in circulation for over 30 years. 
Over the last few decades, DENV has re-emerged in various serotypes and is causing mayhem in the 
lives of many. Dengue is dreaded for the severe fever it causes in its advanced stage. Dengue has the 
reputation of what is known as Dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). 
 
Dengue remains an unmet medical need that demands prompt attention. There remains no cure or 
preventative therapy due to the intransigence nature of this flavivirus. Its tenacity to resist antiviral 
therapy has left the scientific community with the burden of finding new and accelerated techniques to 
curb this virus. The onus is on scientists to probe further into understanding the Dengue virus by the 
use of cheminformatics and bioinformatics tools in the pursuit for an inhibitor against this pernicious 
virus. Of the Dengue structural and non-structural enzymes, the NS5 RNA-dependent RNA polymerase 
has been established as a promising target due to its conserved structure amongst all serotypes and its 
lack of an enzymatic counterpart in mammalian cells. 
 
Attempts have been made to design vaccines and small drug molecules as potential inhibitors against 
DENV. The virus however is resilient, and exists in 5 serotypes with numerous strains under them, 
thwarting the efforts of researchers to curb its spread. This prompted us to design a study that would 
address the above challenges by use of CADD tools, which elaborated on the design of target-specific 
inhibitors of DENV from an atomistic perspective. This included a pharmacophoric approach, which 
utilized computational software to map out a pharmacophore model against multiple flaviviruses, as 
well as a focused review on DENV serotype 2 and 3, which included a route map toward the design of 
target-specific DENV RdRp inhibitors. 
 
We believe that these findings will aid in mitigating the effects of the DENV in the lives of 
compromised individuals, as well as prevent the transmission of DENV from patients to healthy 
individuals. 
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PREFACE 
This thesis is divided into six chapters, including this one: 
 
Chapter 1: 
This is an introductory chapter that addresses the background, rationale and relevance of the study as 
well as the proposed aim and objectives. The general outline and structure of the thesis concludes this 
chapter.  
 
Chapter 2:  
This chapter provides a comprehensive literature review on the DENV epidemic and the urgent research 
taking place toward the development of FDA approved inhibitors of the virus. Included in this chapter 
is the epidemiology, historical background, life cycle, viral diagnostics, modes of transmission, DENV-
linked neurological diseases, viral characteristics (mechanistic and structural), viral/host drug targets, 
specifically the RdRp protein and the design of potential inhibitors in DENV rational drug design and 
discovery. 
 
Chapter 3:  
This chapter conceptualizes computer-aided drug design by discussing a various molecular modeling 
and molecular dynamic techniques and applications. The computational tools needed to investigate 
comparative enzymatic structural/conformational characteristics as well as methods used to analyze 
binding affinity are elucidated upon.  
 
Chapter 4: (Accepted Manuscript- this chapter is presented in the required format of the journal 
and is the final version of the submitted manuscript) 
This chapter demonstrates a unique route map entitled “An “All-in-one” pharmacophoric architecture 
for the discovery of potential broad spectrum anti-flavivirus drugs”, demonstrating potential drug 
targets, strategies for design and computational software available to map out a pharmacophore model 
against flaviviruses. This article has been accepted in Applied Biochemistry and Biotechnology 
(Manuscript ID: ABAB-D-17-01159) (IF =1.75). 
 
 
 V 
Chapter 5: (Accepted Manuscript- this chapter is presented in the required format of the journal 
and is the final version of the submitted manuscript) 
This chapter investigates the second objective of the thesis and is entitled “Using bioinformatics tools 
for the discovery of Dengue RNA-dependent RNA Polymerase Inhibitors.” 
Narrowing down from the first study, this study focused on one flavivirus that is the basis for the rest 
of the flavivirus in terms of drug design and intervention methods. The most pathogenic serotypes were 
selected and discussed. Popular inhibitors were identified and docked to DENV and their binding 
affinities were discussed. This article has been accepted in PeerJ (Manuscript ID: 2018:01:23118:0:1) 
(IF = 2.35). 
Chapter 6:  
This is the final chapter that proposes future work and concluding remarks. 
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CHAPTER 1 
Introduction 
 
1.1 Background and Rational 
 
The Flaviviridae family is named from the Latin word flavus due to the jaundice caused by infection 
with the Yellow fever virus. It constitutes of the species Flavivirus, Pestivirus, Pegivirus 
and Hepacivirus 1. Of the four species, Flaviviruses have become the most conspicuous in the 
medical field 2,3. The yellow fever virus is the prototype for the Flavivirus genus as Flavivruses 
were discovered during yellow fever epidemic investigations. The genus contains over 90 viruses 
with West Nile, Zika, Dengue, Japanese encephalitis and Yellow fever being viruses to note 4,5. 
 
Flavivirus case reports have been alarming over the last decade. The Zika virus has been reported 
in 42 countries, and there is an estimate of 1.5 million reported cases 6,7. Dengue virus (DENV) 
case reports have been noted in 128 countries 7,8. In 2002, 142 cases of West Nile were reported in 
the USA alone 9, and Japanese encephalitis has about 30-50 000 case reports annually in Asia 10. 
These two flaviviruses share the same antigenic complex, and though they were once dominant in 
specific locations, they have spread across the continents at alarming rates 11,12. The Yellow fever 
virus has claimed 117 lives in Angola, and continues to cause distress in West and East Africa. It 
is worthy to note that of the mentioned flaviviruses, Yellow fever is the only one with a vaccine 
against it. The vaccination of travellers entering and leaving the borders of East and West Africa 
has caused a blockade in the spread of Yellow fever to unaffected countries 13,14. The international 
science and research community has summoned researchers to accelerate flavivirus investigations 
due to the unprecedented outbreaks of great magnitude 15. 
 
From the aforementioned flaviviruses, DENV stands out as the “black sheep” of the flaviviridae 
family. This statement can be justified by its unyielding nature to antiviral therapy and rapid 
mutation rates 16–19. The first DENV vaccine trial left scientists with mixed feelings. Some 
welcomed the vaccine that provided immunity against 3 of the 4 serotypes. Others were 
disappointed that overall it was ineffective and showed no protection against the common strain 
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that was circulating at that moment, serotype 2 20,21. In order for a vaccine to be deemed effective, 
it must provide immunity against all 4 serotypes. Should an individual be vaccinated against 1 
serotype, they will never be infected with that serotype again. If the individual however is 
subsequently infected with a different serotype, he or she will have an increased risk of developing 
severe DENV illness 22. The obstinate nature of DENV is caused by its recurring mutations. Its 
periodic appearances in 1986 eventually led to its major debut in 2004 were it presented itself with 
4 serotypes in an outbreak 23,24. These 4 serotypes, DENV1-4, are reported to have been in co-
circulation for as long as 30 years 25. Among these 4 serotypes, each serotype presents further 
challenges of various strains and mutation of strains within the serotype.  Studies have shown that 
DENV viral etiology and serotype is constantly changing 25–27. Clade replacements have also been 
noted within the DENV serotypes. An increase in one serotype leads to an abundance of the same 
serotype, simultaneously decreasing the prevalence of another serotype28–30. These never-ending 
fluctuations have made antiviral therapy onerous. In the midst of this mayhem to find a vaccine and 
antiviral drug that is effective against all 4 serotypes, and account for the potential serotype 
mutations, a 5th serotype emerged thus perpetuating DENV’s stubborn nature to respond to 
treatment 31–33.  Research that has been channelled towards finding inhibitors against the 4 serotypes 
has to be readjusted to accommodate the 5th serotype, further complicating the current state of 
affairs in finding a vaccine and antiviral drugs for DENV. The battle remains to find antiviral 
therapy against DENV.  
 
A divergence from conventional methods of drug design and discovery to novel techniques has 
been warranted by the ever-mutating DENV. Computer-Aided Drug design is a useful strategy to 
by-pass many hurdles encountered during drug discovery and design, with the major ones being 
time and money. Certain computational tools can be employed to identify and landscape inhibitors 
against flaviviruses 34.  
 
Due to the paucity of fundamental research in the previously neglected tropical disease, we have 
utilized key computational techniques to fill the gap in drug design research against flaviviruses. In 
this thesis we will be looking at identifying and designing possible inhibitors, based on 
pharmacophoric features of popular FDA approved drugs that have better potency thus giving 
insights toward novel viral drug targets against this new epidemic. 
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1.2 Aim and objectives 
 
The principal purpose of this thesis is to identify, characterize and map out inhibitors which 
are more efficient and effective for DENV virus treatment by the use of Computer-Aided Drug 
Design techniques. 
In order to accomplish this, the following objectives were outlined: 
 
1. To design an “All-in-one” pharmacophoric architecture for the discovery of potential broad 
spectrum anti-flavivirus drugs by: 
 
1.1. Identifying an experimentally validated inhibitor and assess its physicochemical 
properties for all 5 flaviviruses. 
1.2. Performing MD simulations to create MD ensembles of flavivirus RdRp inhibitor systems. 
1.3. To landscape a pharmacophore model based on free energy calculations (MMGBSA) and 
per residue decomposition analysis. 
 
 
2.  To provide a comprehensive cheminformatics based review for the discovery of DENV 
serotypes 2 and 3 inhibitors. This may be achieved by: 
 
2.1 Sequence and structural analysis of the RdRp of DENV. 
2.2 Active site classification of the DENV RdRp. 
2.3 Identification of potential RdRp inhibitors against DENV. 
 
 
1.3 Novelty and Significance of study 
 
Dengue has been declared a global threat by the World Health Organisation(WHO) 7,17. It has 
savaged the lives of many, and continues to do so at alarming rates 8. The Dengue virus has 
been in circulation for over 30 years, and only recently has it become a nuisance to the health 
community 25. One of the most devastating effects of DENV is its teratogenic properties. 
Vertical transmission leads to babies born with neurological disorders and thus experience 
impaired growth and retardation 35–37. 
 4 
 
Notable progress has been made in mapping out inhibitors against DENV 38–41. Despite these 
efforts, there still remains no approved drug or vaccine for Dengue therapy. This is due to 
DENV’s serotypes. Mutations have led to the co-existence of 5 serotypes of DENV which in 
turn have numerous strains under them. The constant evolution of DENV has led to some 
inhibitors being nullified as potential treatment 23,42. In addition, the inhibitors so far have 
elevated toxicity issues and have not been validated for use in humans 15,43–45. There is therefore 
a need of constant development in drug design. This has prompted us to investigate potential 
inhibitors, based on pharmacophoric features of popular FDA approved drugs, which are more 
efficient and can address all serotypes of the DENV. 
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CHAPTER 2 
 
2. Background on Dengue virus 
 
2.1 Introduction 
 
Members of the flaviviridae family have caused a widespread morbidity and mortality throughout 
the world. There are several species under the flavivirus genus that have caused, and continue to 
cause detrimental effects in people’s health. Viruses of concern include the Zika virus, West Nile 
virus, Dengue virus, Yellow fever virus and Japanese encephalitis virus. These viruses are the 
causal agents of the most important emerging diseases that have no available treatment and 
prevention measurements to date 1,2. 
 
Dengue is an arbovirus whose neuro invasive effects have set the alarm bells ringing over the last 
decade. Dengue is one of species under the flavivirus genus. Dengue virus is the causative agent of 
Dengue fever (DF) and Dengue haemorrhagic fever/Dengue shock syndrome (DHF/DSS). It affects 
people of all ages from neonates to geriatrics. It is closely related to other mosquito borne viruses 
including Zika, Yellow fever and West Nile 2. The primary vector for DENV and viruses of its 
nature is the Aedes Aegypti mosquito found in tropical and sub-tropical areas 3.  
 
This chapter contextualizes the current research on DENV, including previous outbreaks, 
pathogenesis and life cycle of the virus. The structural characteristics of DENV will also be 
reviewed, thus distinguishing possible viral targets in the design of effective and non-toxic 
therapeutics. 
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2.2 Epidemiology and Transmission 
 
The first probable record case of Dengue fever is found in the Chinese medical encyclopedia from 
the Jin Dynasty (265-420AD)4. It referred to a water poison related to flying insects 5. Benjamin 
Rush confirmed the first case report in 1789. He coined the term break bone fever because of the 
myalgia and arthralgia symptoms that accompany Dengue fever 6,7. Severe Dengue was first 
recognized in the 1950s in the Philippines and Thailand.  Before 1970, DENV was only experienced 
in 9 countries. Over the years it has spread to most Asian and Latin American countries, and has 
become the leading cause of hospitalization among children. Dengue is now a pandemic in over 
100 countries in Africa, America, South-east Asia, the Eastern Mediterranean and the Western 
Pacific.  The most affected areas are south-east Asia and the Western Pacific 8,9. 
 
Dengue has shown a 30-fold increase globally over the past five decades. It is estimated that 50 to 
100 million new infections occur annually in more than 100 countries. Death tolls reach an 
astonishing figure of 20 000 a year 10. In some Asian and Latin American countries, severe DENV 
is a leading cause of serious illness and death among children. Across the Americas, South-East 
Asia and Western Pacific, cases exceeded 1.2 million in 2008. This number surged to over 2.2 
million in the year 2010, and has continued to increase in the subsequent years. The number of case 
reports is not only increasing, but outbreaks are being noted. Dengue has also manifested itself in 
different serotypes. Besides the already mention areas affected by DENV, Europe is under threat 
for a potential outbreak. Local transmission of Dengue was reported for the first time in France and 
Croatia in 2010 9,11,12. Statistics show that over 2.5 billion people, being over 40% of the total 
world’s population, are vulnerable to DENV. This has made Dengue the most important acute 
systematic arthropod-borne viral infection in humans 8. 
 
This rampant transmission of DENV has been due to the increase in travel across the continents. 
Disease carriers travel to regions with no cases of DENV and infect the people around them. In 
addition, climate changes have allowed the spread of mosquitoes across continents, allowing for 
increased infection rates 13,14. Another reason for the continental dissemination of the virus is the 
identification of new modes of viral transmission. Studies have evidenced DENV to be transmitted 
through perinatal transmission, blood transfusion and sexual transmission 3,15,16. The co-existence 
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of 5 DENV serotypes further exacerbates the situation as when DENV spreads, a new strain 
emerges which is more virulent than the previous one, making it more difficult to eradicate 17–19. 
 
 
2.3 Characterizing DENV 
 
With the upsurge of DENV case reports, much research has been allocated into providing a better 
understanding of the major physiological and molecular mechanisms underlying this infectious 
disease. It is therefore imperative to understand the DENV structure and life cycle so as to design 
anti-therapeutic agents and delve into the structural implications of DENV drug resistance 
mutations. The Dengue virus is highly mutable given the presence of its 5 serotypes and vast 
number of strains 20. This fortifies the challenge of designing efficient inhibitors against the virus. 
 
2.3.1 Life cycle of DENV 
 
 The Dengue virus must exploit cell machinery in order to survive and complete its infectious cycle. 
Subsequent to viral entry into host, the DENV virion attaches to the surface of target cells by 
interactions between the envelope protein and the host cell surface receptors. The host cell receptors 
that have been evidenced to mediate virion endocytosis include phosphotydylserine receptor, AXL, 
as well as DC-SIGN, TIM-1 and Tyro3. Virions undergo this receptor-mediated endocytosis and 
are internalized to the cell cytoplasm. The viral envelope is then uncoated and the viral RNA is 
released into the cell cytoplasm. The viral RNA is then translated produce a large polyprotein at 
the endoplasmic reticulum and is subsequently cleaved into the individual viral proteins, leading to 
the replication of the viral genome. The viral RNA as well as the structural and non-structural 
proteins, and some host proteins are involved in the packaging of the viral complex into vesicles 
and assemble by budding into the endoplasmic reticulum, whereas immature viral particles utilize 
the host secretory pathway, where virion maturation occurs followed by release from the cell. 21–24 
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Figure 2.1: Life cycle of the DENV virus 24. 
 
2.3.2 Structural Characteristics of DENV 
Dengue is an enveloped, non-polyadenylated positive-strand RNA virus whose viral genome 
comprises of a positive-sense  RNA virus approximately 11kb in size 25. This genome encodes a 
single open reading frame flanked by highly structured 5’- and 3’ UTRs. There are key RNA 
elements in the viral genome that are essential for DENV replication; the stem-loop(SLA), the 
cyclization elements present on both sides of the genome, the capsid-coding region hairpin element 
(cHP) and the highly conserved 3’ stem-loop(3’SL) 23. At the 5’end is found the SLA which 
functions as the promoter for RNA synthesis. This promoter is also responsible for binding and 
activating the polymerase NS5 that will in turn initiate RNA synthesis at the 3’ end of a circulized 
viral genome 26. The cHP is located in the capsid protein-coding sequence. It is required for 
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efficiency in the viral replication process. The terminal of 3’ end presents genomes that fold into a 
highly conserved 3’SL. Upstream of this loop is the conserved sequences CS1 which contain the 
cyclization sequence also needed for RNA replication. The RNA genome also encodes 3 structural 
proteins that form the components of the virion: the capsid (C), precursor membrane (prM) and the 
envelope (E). In addition to this assembly are seven non-structural (NS)  proteins namely NS1, 
NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5 26–29. These non-structural proteins are involved 
in virus assembly, viral RNA replication and modulation of the host cell responses.  
 
 
Figure 2.2: Dengue polyprotein demonstrating available protein crystal structures (PDB codes: 
1R6R, 4UTC, 4O6B, 2FOM, 2VBC, 1L9K, 5K5M) (Prepared by Authors). 
 
 
 
 
2.3.3 DENV Pathogenesis and Clinical Features 
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The mosquito borne viral infection comes with severe flu-like illness when initially acquired. A 
high fever of 40°C/104°F accompanied by either severe headache, pain behind the eyes, muscle 
and joint pains, nausea, vomiting, swollen glands or rash confirms Dengue infection. This fever is 
known as break bone fever as it is accompanied by arthralgia and myalgia. Symptoms usually last 
for 2–7 days, after an incubation period of 4–10 days after being bitten by an infected mosquito. 
Dengue fever seldom causes death. Severe Dengue (Dengue haemorrhagic fever/Dengue shock 
syndrome (DHF/DSS) is, however, a potentially deadly complication due to plasma leaking, fluid 
accumulation, respiratory distress, severe bleeding, or organ impairment. Caution signs crop up 3–
7 days after the first symptoms in conjunction with a decrease in temperature (below 38°C/100°F). 
They also encompass severe abdominal pain, persistent vomiting, and rapid breathing, bleeding 
gums, fatigue, restlessness and blood in vomit. The subsequent 24–48 hours of the critical stage 
can be fatal 30–32. Adequate medical care is therefore imperative to evade complications and death.  
 
The simultaneous presence of two or more infections which increases the graveness and duration 
of a disease is defined as co-infection. Studies have reported incidence of DENV and CHIKV co-
infections in humans and vectors 33,34. Both infections pose overlapping clinical presentation and 
diagnosis can be challenging. In order to differentiate the two, there are major symptoms to look 
out for. Dengue fever classically is accompanied by a severe headache, eye pain, and prominent 
myalgia and enlarged lymph nodes. Chikugunya(CHIKV) is also characterized by a severe 
headache and enlarged lymph nodes, but instead of general myalgia, it is marked by joint pain and 
arthritis 35–38. It is imperative to distinguish these two so as to manage the symptoms accordingly. 
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2.4 Rationale of DENV RdRp as Potential Therapeutics Targets 
 
2.4.1 NS5-RdRp  
 
The NS5 is the largest viral protein that has caught the eye of numerous researchers 39,40. It is the 
most conserved non-structural protein amongst the viral proteins. The NS5 is a bi-functional protein 
that contains 900 amino acids. The S-adenosyl methionine transferase is found on the N-terminal.  
On the C-terminal, residues 270 to 900 make up the RNA-dependent RNA polymerase (RdRp). 
 
The RNA-dependent RNA polymerase (RdRp) domain of the NS5 protein will be explored in this 
study by the use of cheminformatic tools in the search for an inhibitor to alleviate the DENV. The 
RdRp plays a significant role in RNA synthesis by catalyzing the replication of RNA synthesis via 
a two-step mechanism, thus validating it as a target for antiviral therapy 41,42.  
 
The high genetic diversity of DENV virus serotypes is a result of its high mutation rate caused by 
error-prone RdRp, which lacks proofreading activity and generates approximately one mutation 
per round of genome replication 43,44. Genetic recombination is also known to cause intra-serotype 
genetic variation in DENV 45–48. 
The architecture of the DENV RdRp adopts the canonical right-hand conformation comprising of 
fingers, palm and thumb surrounding its polymerase active site 49. This applies to most polymerases 
50,51. Dengue however has the nuclear localized structure (NLS) playing a major role in its structural 
formation 40,52. The NLS domain signatures are distributed between the fingers and thumb 
subdomains from residues 316-415. They are the hotspots for interactions with other viral and host 
proteins 53,54 55. Alterations within the NLS region lead to structural destabilization 52,56. The RdRp 
can be divided into three subdomains: the fingers, palm and thumb 57. 
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Figure 2.3: Complete Structure of DENV RdRp (Prepared by Author). 
Finger domain 
The finger   domain is divided into two subdomains. The first strand is a beta-strand-rich (β) 
subdomain and the fingers found on this strand are termed beta fingers 50. The other strand is rich 
in alpha-helices (α) and therefore the fingers found in this region are alpha fingers. In addition, the 
finger region has four flexible loops, β1-α2 loop, α3-α4loop, α6-α7 loop and α7- α8loop. Overall, 
the residues in the finger region are from 273-600 51,58,59. The α1-9 residues are from 273 to 496, 
and α 12 to β 3 residues are from 543 to 600 51,60. The fingers subdomain is located at the top of the 
RdRp molecule and appears to be more mobile than the palm and thumb domain 54,61,62. 
Palm domain  
The palm domain is the catalytic domain and encompasses a folding motif that is highly conserved 
among polymerases 52,57. The palm constitutes of 2 antiparallel β-strands, β4 and β5, and is 
surrounded by eight helices which are α11 to α13 and α16 to α20. The residues found on the palm 
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domain are 497 to 542 on α 10, α 11 and 310 helix g1, and residues 601 to 705 on α 14-to 310-
helix g2. There are six conserved sequence motifs located in the palm region 51,58,63–67. 
Thumb domain 
The thumb domain molds the C-terminal end of the RdRp, 68 and is composed of residues 706 to 
900 on the β 6 to α 23 52,58. It has portrayed itself to be the most structurally variable among known 
polymerase structures 41,69. The thumb domain contains two conserved sequence motifs. Motif E 
forms an antiparallel β-sheet wedged between the palm domain and several α-helices of the thumb 
domain 61,70. In conjunction with the finger tips, the path chosen by this loop greatly contributes to 
the shaping of the RNA template tunnel 52,71,72.  
Priming loop 
A second loop consisting of amino acids 782-809 forms the priming loop which partially blocks 
the active site. The priming loop plays a key role in initiating the RdRp complex 73–75. This path is 
stabilized by internal interactions that include hydrogen bonds. This assists in maintaining its 
orientation in relation to the protein structure 61,76. It is also called the G-loop because it corresponds 
to motif G in primer dependant RdRps. It’s tip is partially disordered in the flavivirus RdRp 
structures thus suggesting conformational flexibility 60,77. 
 
2.4.2 Potential Inhibitors of DENV  
Identification of small molecules that inhibit a major step in the viral cycle demands a detailed 
biochemical and structural characterization of the RdRp protein essential for replication 78. The 
development of an antiviral drug for DENV is complicated due to the presence of its five serotypes. 
This is due to the fact that when protection against one serotype is being generated, protection 
against other serotypes lasts only a few months 79. Over the years, inhibitors that have shown 
potential antiviral activity against the RdRp region have been discovered. These inhibitors, 
however, come with multiple challenges including elevated toxicity levels. Scientists are therefore 
still battling to find an inhibitor that is potent, efficacious and non-toxic for the treatment of DENV 
virus 58,78,80. 
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Table 2.1: Popular flavivirus inhibitors bound to DENV RdRp. 
Compound 
Mechanism of 
Action 
Binding 
Energy 
(kcal/mol) 
Pose 
Amino acid 
residues 
NITD008 
Inhibitor of all 4 
DENV serotypes 
[93–95]. 
-5.5 
 PHE 127   
ARG 210    
LYS 130     
VAL 131    
ASN 134    
ALA 135    
GLN 332   
TYR335     
TYR 336 
 
 
Balapiravir 
A cytidine 
nucleoside that is a 
domain RdRp 
inhibitor [94]. 
-6.1 
 TYR451 
ASN452 
VAL577 
ARG594 
VAL576 
LYS575 
SER593  
Lycorine 
A potent flavivirus 
inhibitor in cell 
culture through 
suppression of 
viral RNA 
replication 
[94,96]. 
-5.8 
 TRP 474    
TRP 477      
ILE 473      
SER 470    
VAL 579     
LYS 578    
MET 589 
Ribavirin 
Significant in vitro 
activity against 
flaviviruses 
[98,99]. 
-5.0 
 LYS 78     
ASN 452     
GLN 580    
VAL 579     
VAL 310      
ILE 473  
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7-deaza-
2’methylade
nosine 
Potent ZIKV 
inhibitor that 
reduces viremia 
[100] 
-5.5 
 ILE 283      
GLU 286      
ILE 473     
MET 453    
MET 589    
TYR 451 
3’Dgtp 
GTP analogue that 
inhibits DENV-2 
RdRp but has a 
low IC50 value 
[67] 
-5.0 
 MET 589    
VAL 579     
LYS 578    
ASN 452    
MET 453    
VAL 310    
TYR 308 
2’O-metil 
GTP 
Showed low IC in 
vitro DENV-2 
[67]. 
-5.3 
 THR 343    
THR 313    
SER 470    
TRP 477    
GLY 349    
ASN 452 
NITD 203 
Inhibitor of all 4 
DENV serotypes 
[93]. 
-6.4 
 VAL 358    
GLY 599    
TYR 451      
ILE 591      
GLY 601    
SER 600            
LYS 578     
VAL 538 
Favipiravir 
A pyrazine-
substitute 
compound that has 
shown to inhibit 
flavivirus 
mortality in 
rodents [102,103]. 
-4.0 
 
ASN 452    
TYR 451    
VAL 579     
LYS 578  
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Ivermectin 
Pretreatment of 
ivermectin with N-
(-4-
hydroxyphenyl) 
inhibits the 
nuclear 
localization of 
NS5 [106]. 
-5.3 
 ASN 452    
LYS 578    
MET 589    
VAL 579     
VAL 310    
MET 453 
 
2.5 The Scientific Advancements of DENV Anti-viral Therapy 
Dengue infection has been found to be associated with severe and fatal hemorrhagic fever 
conditions as mentioned above. The concerns of the scientific and clinical community are the 
consequences of DENV viral mutations, thus suggesting the urgent need for viral inhibitors. There 
have been large strides in vaccine development against the virus. The first registered vaccine was 
Dengvaxia by Sanofi Pasteur in Mexico 2016 81–83. The vaccine however does not cover immunity 
against all DENV serotypes, thus getting the vaccine and being exposed to other serotypes not 
covered by the vaccine leaves one at risk of acquiring severe Dengue infection 81. Vaccines against 
DENV are still under evaluation in clinical trials 84,85. Rapid rational drug design and discovery 
research is fundamental in the production of potent inhibitors against the virus to annihilate it. There 
are no FDA approved drugs against DENV 5,8,86. There are potential inhibitors that have shown 
antiviral activity against DENV. They, however, come with a plethora of side effects including 
high toxicity levels 87–90. Therefore, there remains a need for the pursuit of antiviral therapy that 
will ameliorate the current situation with DENV, and put an end to its dynasty. 
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CHAPTER 3 
3. Molecular Modeling and Bio-Computational Strategies to Drug Discovery and Design 
 
3.1 Introduction  
 
There has been a paradigm shift in the design of drugs and other biological compounds in the 
medical world today. Novel methods of drug design are continuously being exploited in an 
endeavour to improve efficiency and encounter challenges faced during the drug design process 1,2. 
Molecular modeling, also known as computational chemistry is a rapidly growing discipline of 
science in the research community. It encompasses theoretical and computational methods used to 
simulate the behaviour of molecules 3. According to Pensak, molecular modeling is defined as 
“anything that requires the use of a computer to paint, describe or evaluate any aspect of the 
properties of the structure of a molecule” (Jensen, 2002, )5. They are various disciplines within 
molecular modeling. These include computational chemistry, drug design, cheminformatics, 
bioinformatics and computational biology amongst many others 6. For the purpose of this study, 
the methods focused on included computational chemistry, cheminformatics tools.  
 
Computational chemistry has become the mainstream of drug design and discovery in the medical 
domain. It entails the use of algorithms that perform calculations, data processing and automated 
reasoning tasks to solve a class of chemical problems 7. By definition, computational chemistry is 
a subsidiary of chemistry that entails the use of computer simulation to aid in the solution of 
chemical problems. It uses equations encapsulating the behaviour of matter on an atomic scale and 
uses computers to solve these equations, calculate structures and properties of molecules, gases, 
liquids and solids and to explain and predict chemical phenomena 7–9.  It provides a platform for 
scientists to predict chemical reactions and their outputs using computer software. This by-passes 
empirical processes performed in the laboratory thus saving time and enormous costs that follow 
practical laboratory experiments 10–12. Computational chemistry covers an extensive range of topics 
including quantum chemistry, molecular mechanics and molecular dynamics 13. This chapter 
concentrates on the computational tools and theoretical tools germane to this study. There are two 
basic components used to describe computational chemistry: 
1) Quantum Mechanics 
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2) Molecular Mechanics 
 
Figure 3.1: Schematic representation of the two components of computational chemistry (Prepared 
by Author). 
 
3.2 Quantum Mechanics 
 
Quantum mechanics is the study of the behaviour of matter and energy at the molecular, atomic, 
nuclear and smaller microscopic levels. Quantum mechanics(QM) is also known as quantum 
physics or quantum field theory 14,15. It is the most successful theory in the history of science. The 
quantum hypothesis was suggested by Max Planck in 1900 16. It states that any energy radiating 
atomic system can be theoretically divided into a number of discrete energy elements such that 
each of the energy elements is proportional to the frequency with which each of them radiate energy 
individually 17. Planck theorized that energy was transferred in portions called quanta, hence the 
name quantum hypothesis. It is illustrated by the equation below: 
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E=hv     (Eq 3.2.1) 
where E is energy, h is Planck's constant, equal to 6.626068 × 10−34 Joule-second (J-s) and the 
Greek letter v is the photon’s frequency 18–20. 
 
The quantum phenomena can be best explained by the Copenhagen interpretation. Danish physicist 
Niels Bohr and German physicist Werner Heisenberg came up with a set of statements which 
attempt to explain how QM explains our understanding of nature 21. The Copenhagen interpretation 
states that physical systems normally do not have distinct properties prior to being measured, and 
quantum mechanics can only predict the probabilities that measurements will produce certain 
results. It states that a quantum particle does not exist in one state or another, but it exists in all of 
its possible states concurrently. Only upon observation is a quantum particle compelled to choose 
one probability, and this is the state we observe. This explains why a quantum particle is said to 
behave erratically. This state of a quantum particle existing in all possible states at once is called 
an object’s coherent superposition. The sum of all possible states which an object can exist forms 
the object’s wave function. When an object is observed, its superposition collapses and the object 
is forced into one of the states of its wave function 22–24. 
Although there have been many objections to the Copenhagen interpretation, it still remains the 
frequently taught explanations of quantum mechanics 25. The quantum hypothesis laid a foundation 
for many physicists like Albert Einstein, Niels Bohr, Werner Heisenberg, Erwin Schrödinger and 
many others to further develop the field of quantum physics 14,26.  
 
3.2.1 The Schrödinger Wave Function 
 
The Viennese physicist Erwin Schrödinger vetted the Copenhagen theory by the famous thought 
experiment involving a cat and a box. Schrödinger placed a cat in a sealed box and added a flask 
with poison inside the box. Schrödinger proposed that if an internal monitor detects radioactivity, 
the flask will be shattered, releasing the poison thus killing the cat. This challenged the Copenhagen 
interpretation which implies that the cat can be simultaneously alive and dead, a state known as 
coherent/quantum superposition. Schrödinger went on to say that upon observation of the cat, the 
superposition of the cat would collapse into either the cat is alive or dead, not both 27–30. 
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This paradox created by Schrödinger led him to his next theory, which had a great impact in the 
world of quantum physics. At the dawning of the twentieth century, scientific evidence implied that 
atomic particles were wave-like in nature 31. It was feasible to assume that a wave equation could 
explain the behaviour of atomic particles. Schrödinger was the first person to write down a wave 
equation and earned a Nobel prize in 1933 32. Schrödinger argued that Newton’s laws do not apply 
to miniscule things. In other words, the rules used to govern the motion of a car cannot be used to 
explain how an electron or atom works. After a lot of discussion and debate, the wave equation was 
accepted to be a probability distribution 33,34.  
 
The Schrödinger equation, often called the Schrödinger wave function describes all of the possible 
states particles can have including properties like energy, momentum and position. Schrödinger 
utilized mathematical equations to describe the probability of locating an electron on an exact path 
(Schrödinger, 1961).  
The Schrödinger wave equation 36: 
𝐇𝛙 = 𝐄𝛙                                                     (Eq 3.2.2) 
 𝐇 = 𝐓 + 𝐕                                                   (Eq 3.2.3) 
𝐇 = [−
𝐡𝟐
𝟖𝛑𝟐
∑
𝟏
𝐦𝐣
𝐢
(
𝛛𝟐
𝛛𝐱𝟐
+
𝛛𝟐
𝛛𝐲𝟐
+
𝛛𝟐
𝛛𝐳𝟐
)] + ∑ ∑ (
𝐞𝐢𝐞𝐣
𝐫𝐢𝐣
)             (Eq 3.2.4)           
<𝐣𝐢
 
 
The Schrödinger wave function is an integral equation of physics for illustrating mechanical 
behavior. It is a partial differential equation that describes how wave function of a physical system 
evolves over time. When quantum mechanical systems are observed from the Schrödinger equation 
perspective, it is known as the Schrödinger picture, as opposed to viewing quantum mechanical 
systems from the matrix mechanical view point, known as the Heisenberg picture 37–39. 
3.2.2 The Born-Oppenheimer Approximation Theory 
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Max Born and J. Robert Oppenheimer proposed the Born- Oppenheimer approximation in 1927 40. 
This theory assumes that the motion of atomic nuclei and electrons in a molecule can be separated. 
In mathematical terminology, it allows for the wave function of a molecule to broken into its 
electronic and nuclear components. The Born-Oppenheimer theory allows for the Schrödinger 
equation to be solved for the kinetic energy of the electrons alone since the kinetic energy for the 
nuclei remains constant. Electrons are considered to be of lighter weight than the nuclei. This leads 
to the electrons having a greater velocity and moving instantaneously to nuclei movement. The 
distribution of electrons within a molecule is therefore defined by the location of the nuclei 41–44. 
 
The disparity in velocities of the nuclei and electrons allow for the application of the Born-
Oppenheimer approximation, thus minimizing the complexity of the wave function of the 
Hamiltonian equation. The simplified wave function is as follows: 
𝛙(𝐫𝐞𝐥𝐞𝐜) =  𝛙(𝐫𝐞𝐥𝐞𝐜) (𝛙(𝐫𝐧𝐮𝐜𝐥)                  (Eq 3.2.5) 
 
 
Eq 3.2.2 is converted: 
𝑯𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜) =  𝑬𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜)                        (Eq 3.2.6)  
Where HEN denotes a difference between terms based activity to fixed nuclear positions (VNN) or 
their activity to the non-fixed electron positions. Eq. 3.2.5 shows EEN, which is derived from 2 
sources being the fluctuating electron co-ordinates and fixed nuclear co-ordinates.  
 
 
 
(𝐇𝐞𝐥 + 𝐕𝐍𝐍) 𝛙(𝐫𝐞𝐥) =  𝐄𝐄𝐍𝛙(𝐫𝐞𝐥)               (Eq 3.2.7) 
 
 Electronic motion is best described by the electronic Schrödinger equation. This approximation is 
more accurate when it is applied to ground electronic states. Assessment of equilibrated states is 
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only possible once the equation has been solved. The potential energy surface curve also can be 
now constructed 45,46. 
 
 
3.2.3 Potential Energy Surface 
 
The potential energy surface is an effective mathematical representation between molecular 
vibrational motions of a molecule, along with its geometry and its nuclear probability distribution 
by finding solutions to the time-dependent Schrödinger equation. This concept is birthed from the 
Born-Oppenheimer approximation elucidated above, where electrons differ according to the 
positional states of the nuclei in a manner such that the potential energy surface is taken as the 
potential of atoms to collide with each other in a molecule 47,48. A potential energy surface displays 
high potential energy regions, indicating high-energy nuclear arrangements or molecular 
conformations and low energy regions indicating low nuclear energy conformations. The potential 
energy surface is utilized in computational chemistry to analyse the lowest energy state and the 
positional geometry of a molecule at this state 49,50. 
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The potential energy function is thus described as follows: 
 
Figure 3.2: Graphical representation of a 2-D potential energy surface (PES) 
 
3.3 Molecular Mechanics 
 
Molecular mechanics (MM) or force-field methods use classical type models to predict the energy 
of a molecule as a function of its confirmation. This involves predictions of equilibrium geometries 
and transition states, relative energies between conformers or between different molecules 51,52. 
 
Molecular mechanics is a computational method that computes the potential energy surface for a 
specific order of atoms by the use of potential functions that are obtained using classical physics 
53,54. It is based on the following assumptions: 
1) Electrons are treated around a nucleus that is a perfect sphere. 
2) The bonds between molecules are treated as springs. 
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3) Potential functions are dependent on experimental parameters such as force constants and 
equilibrium values. 
4) The potential energy function is the sum of individual functions for bond stretching, angle 
bending, torsional energies, and non-bonding interactions. 
 
Molecular mechanics requires less of a computer than QM methods. It is however restricted by 
certain parameters of equations such as the different force-field for different types of atoms. 
Moreover, it is inapplicable for electronic properties 5556.  
The potential functions generated by molecular mechanics have no absolute meaning. They are 
merely for comparing different configurations of a molecule. Molecular mechanics can be 
beneficial for large molecules such as proteins. Its prime use is mainly in the field molecular 
dynamics 57. MM calculations are often referred to as force field calculations 58. 
 
3.3.1 Potential Energy Function 
 
Atoms are known as the monads in force field methods whereas electrons are not considered as 
single entities. This implies that rather than finding solutions to the Schrödinger equation, explicit 
bonding information must be provided 59. Molecules are described by a “ball and spring” analogy, 
with atoms of different sizes and bonds of different lengths. It was detected that different molecules 
might have structural similarity due to the atoms they are made up of. The notion atom types was 
then coined, and is dependent on the atomic number and chemical bonding fixating it in place 6061 
. The potential energy function (PEF)/force field of a molecular system may be assembled in terms 
of a set of force field energy equations that are solely based on Newtonian classical physics. These 
equations calculate the energy of the system as well as the atom types that construct the molecule 
62. 
 
The following equations best describe the sum of all individual molecular components that make 
up the total potential energy: 
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1. Bond stretching (between directly bonded atoms) 
 𝐄𝐫 =  ∑𝐊𝐫(𝐫 − 𝐫𝟎)
𝟐                                                              (Eq 3.3.1) 
 
2. Angle bending (atoms bounded to same central atoms) 
𝐄𝛉 =  ∑𝐊𝛉(𝛉 − 𝛉𝟎)
𝟐                                                              (Eq 3.3.2) 
 
3. Bond torsion 
𝐄𝛟 =  ∑𝐊𝛟[𝟏 + 𝐜𝐨𝐬(𝐧𝛟 − 𝛟𝟎)]                                                 (Eq 3.3.3)         
4. Non-bonded interactions  (van der Waals and electrostatic) 
 𝐄𝐧𝐛 = [∑ ∑ (
𝐀𝐢𝐣
 𝐫𝐢𝐣𝟏𝟐
−
𝐁𝐢𝐣
𝐫𝐢𝐣𝟔
 )] + [∑ ∑ (
𝐪𝐢𝐪𝐣
𝐃𝐫𝐢𝐣
 )]             (Eq 3.3.4) 
Where: Kr, Kθ, Kϕ are force constants for bond, angle, and dihedral angle and ro, θo, ϕo are the 
equilibrium distance, angle and phase angle. Parameter rij is distance, while Aij and Bij are van der 
Waal parameters. D is the molecular dielectric constant; qi and qj are charge points.  
 
3.3.2 Force Field 
 
In order to describe the time progression of bond lengths, bond angles and torsions, including the 
non-bonding van der Waals and electrostatic interactions between atoms, one uses a force field. 
The force field is a collection of equations and associated constants designed to reproduce 
molecular geometry and selected properties of tested structures 63.  
 
The MM force field was first formulated during the 1970s 59. A force field is a mathematical 
function with a delineated set of parameters. These parameters describe the rapport of molecular 
energy systems to specific particle co-ordinates 64. Commonly used biomolecular force fields 
include: AMBER 65, CHARM 66, NAMD 67, GROMOS 68 and OPLS-AA 69. All force field 
parameters are obtained from either experimental data sources, ab initio or semi-empirical QM 59. 
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Force field functions are assumed to be wholly dependent on atomic orientations. They have been 
used as representatives for describing potential energy surface for different types of molecular 
systems with varying degrees of freedom 70. This force field function must bring depth into 
understanding the specific forces acting within the molecular system. In this thesis, the AMBER14 
force field was implemented to characterise the enzymes, whilst GAFF was used to interpret the 
ligands 71. The AMBER14 force field provides a favourable balance in energy between the helical 
and extended regions of the peptide and protein backbones with improved dihedral torsions 72. 
 
3.4 Molecular Dynamics  
 
Molecular dynamics (MD) is a computer simulation process for analysing the kinetics of atoms and 
molecules. Properties of assemblies of molecules in terms of their structure and the microscopic 
can be expounded using MD simulations. In MD, complex systems are modelled at atomic level 
and the equations of motion are mathematically solved to indicate the time of evolution of a specific 
system, thus allowing a derivation of its kinetic energy and thermodynamic properties through the 
application of computational tools 49,73,74. Atomic trajectories are generated through the integration 
of Newton’s equations of motion for atoms on an energy surface. This can be illustrated by the 
equation below: 
𝐅𝐢 =  𝐦𝐢
𝐝𝟐𝐫𝐢(𝐭)
𝐝𝐭𝟐
                                                      (Eq 3.4.1) 
 
Where ri (t) is the particle position vector, t is time-evolution, m is the mass of the particle and Fi 
depicts the interacting force on the particle.  
 
Molecular dynamics can be categorized into 4 continuous technical steps that are repeated 
numerously to generate a trajectory. The categories can be summarized by: 
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Figure 3.3. Cycle of molecular dynamics steps  
 
The steps are outlined below: 
1) The fundamental requirements of the biomolecular system are defined: 
 The co-ordinates of each atom  
 The bond characteristics between each atom 
 The acceleration of atoms 
 
2) Each atom’s potential energy is computed. 
3) The energies from step are then utilized to solve the equation of motion. 
4) The new state of the system needs to be saved, and the atoms’ co-ordinates changed, ad 
step forward in the simulation taken. The cycle then restarts from step 1.  
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3.4.1 Molecular Dynamics Post-Analysis 
 
Molecular post-dynamic techniques and calculations have been used to describe the protein features 
in studies conducted in this thesis. Molecular dynamic trajectories are a product of the run 
molecular dynamic simulation. They can be defined as sequential snapshots characterized by both 
positional co-ordinates and velocity vectors 74,75. In this study, post dynamic analysis of the 
trajectories is critical for determining the: 
1) Energetic and conformational stability of the biomolecular system.  
2) The characteristics of the system’s small molecule binding landscape and the 
thermodynamic energy fluctuations along the system’s clustered trajectory. 
3) Dynamic conformational features or variability of the biomolecular system. 
 
3.4.1.1 System Stability 
Convergence: 
 
Convergence is an empirical description of protein dynamics. It specifically describes protein 
dynamics based on bond types and bond angle vibrations during the unfolding of a protein. This 
fusion toward equilibrium and portrayal of a conclusive plateau is impertinent for a MD trajectory 
to be accurate and reproducible. At this plateau, the protein-ligand system displays energetically 
stable conformations 76. 
 
Root Mean Square Deviation (RMSD): 
 
Spatial difference between two static structures of the same trajectory measure the deviation of a 
complex 77. The RMSD of a trajectory is defined as: 
𝐑𝐌𝐒𝐃 =  (
∑ (𝐑𝐢 − 𝐑𝟏
𝟎)𝟐𝐍
𝐍
)
𝟏
𝟐
                                (Eq 3.4.2) 
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Root Mean Square Fluctuation (RMSF): 
 
The root mean fluctuation (RMSF) of a protein measures residue’s Cα atom fluctuations is based 
on the average protein structure along the system’s trajectory. The RMSF captures the fluctuation 
for each atom around its average position 78,79. It is calculated using the equation below: 
𝐬𝐑𝐌𝐒𝐅 =  
(𝐑𝐌𝐒𝐅𝐢 − 𝐑𝐌𝐒𝐅)
𝛔 (𝐑𝐌𝐒𝐅)
                                         (Eq 3.4.3) 
 
Where: RMSFi is the RMSF of the ith residue, from which the average RMSF is subtracted. This is 
then divided by the RMSF’s standard deviation to yield the resultant standardized RMSF.  
 
3.4.1.2 Binding Free Energy 
Calculations of binding energy are crucial in computational chemistry studies as they are the end 
point method that accounts for the ligand-receptor interactions. Approximations of binding free 
energy leads to the development of various algorithms including energy perturbations, 
thermodynamic integration, molecular docking calculations amongst many.  
 
The Molecular Mechanics/Generalized Born Surface Area method (MM/GBSA) methods have 
been regarded as the most accurate and efficient in estimating binding free energies for biological 
macromolecules 80. The free binding energy () computed by these methods for a protein system 
which comprises of the complex, ligand and receptor can be represented as: 
∆𝐆𝐛𝐢𝐧𝐝 = 𝐆𝐜𝐨𝐦𝐩𝐥𝐞𝐱 − 𝐆𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 − 𝐆𝐥𝐢𝐠𝐚𝐧𝐝                                 (Eq 3.4.4) 
∆𝐆𝐛𝐢𝐧𝐝 = 𝐄𝐠𝐚𝐬 + 𝐆𝐬𝐨𝐥 − 𝐓𝐒                                                          (Eq 3.4.5) 
𝐄𝐠𝐚𝐬 = 𝐄𝐢𝐧𝐭 + 𝐄𝐯𝐝𝐰 + 𝐄𝐞𝐥𝐞                                                           (Eq 3.4.6) 
𝐆𝐬𝐨𝐥 = 𝐆𝐆𝐁/𝐏𝐁 + 𝐆𝐒𝐀                                                                     (Eq 3.4.7) 
𝐆𝐒𝐀 = 𝛄𝐒𝐀𝐒𝐀                                                                                   (Eq 3.4.8) 
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The term Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele, and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy contribution 
from the polar states, GGB and non-polar states, G 81,82.  
 
3.5 Pharmacophore generation 
 
The principle behind computer-aided molecular design methods is to curtail the costs associated 
with discovery and development of potential drugs. One way this can be achieved is by the 
formation of a pharmacophore 83. A pharmacophore model is a geometrical description of the 
chemical functionalities that are mandatory in order for a ligand to interact with the receptor. Paul 
Ehrlich birthed the idea of a pharmacophore in the 1800s. At that time, it was established that 
specific chemical groups were liable for certain biological effects, and that molecules with similar 
effects had similar functions in common. Schueler coined the word pharmacophore in 1960. He 
defined a pharmacophore as “a molecular framework that carries (phoros) the essential features 
responsible for a drug’s (pharmakon) biological activity 84,85. The definition shifted from chemical 
groups to patterns of abstract features. The International Union of Applied Chemistry decreed a 
definition that still stands today; 
 
A pharmacophore is the ensemble of steric and electronic features that is necessary to ensure the 
optimal supramolecular interactions with a specific biological target and to trigger or block 
biological response 86. A pharmacophore therefore does not represent a real molecule or a set of 
chemical groups, but is rather an abstract concept 87. The pharmacophore concept has become a 
vital tool in Computer-Aided Drug Design. Atoms or functional groups in a molecule that exhibit 
specific features that are related to molecular recognition can be reduced to a pharmacophore 
feature 88–90. 
 
 
3.6 Cheminformatics Tools Utilized in this Study 
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The focal point of cheminformatics is to analyze, simulate and manipulate chemical 
information in order to accelerate decision making and reduce expenses in the areas of drug 
lead identification and optimization in the process of drug discovery 91. Cheminformatics, 
therefore seeks to fill the void between surging DENV case reports and absence of 
antivirals. This study adopts cheminformatics and bioinformatics tools in a quest to map 
out an inhibitor against the most pathogenic DENV flavivirus serotypes 2 and 3. By the use 
of bio-computational techniques, comprehensive informational data will be provided, 
which will allow for the identification and design of inhibitors against DENV infections.  
 
3.7 Other Molecular Modeling Tools Used in this Study 
 
Molecular Docking 
 
Molecular docking has become a fundamental tool in the drug discovery industry. It employs 
multiple methods to predict the binding affinity and configuration of a complex. Most general use 
of docking is in ligand-receptor complexes, although other uses are documented. There are two 
major steps in docking: 
1. Sample conformations of a ligand in the active site of protein. 
Different algorithms may be used when sampling the numerous conformations of the 
docked complex. This can be the “lock and key” model which describes the ligand and 
receptor as rigid structures, or the ligand may reflect flexibility by random or simulation-
based methods. The latter algorithm is the frequently used method as it permits a more 
realistic fit of the ligand to the protein 92.  
2. Ranking the different conformations by scoring function. 
 The scoring function may be based on statistically preferred contacts, MM force fields or 
pre-existing protein-ligand binding affinities 92. 
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Molecular docking comes with many inconsistencies. Docked compounds are often criticized due 
to incorrect binding sites or choice of docked complex. Due to these concerns, all docked 
complexes in this study were verified with MD simulations and the stability of the ligand at the 
active site was demonstrated.  
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CHAPTER 4 
An “All-in-one” Pharmacophoric Architecture for the Discovery of Potential Broad Spectrum 
Anti-flavivirus drugs 
 
Abstract 
Background: A precipitous increase in the number of flaviviral infections has been noted over the 
last five years. Despite these outbreaks, treatment protocols for infected individuals remain 
ambiguous. Numerous studies have identified NITD008 as a potent flavivirus inhibitor, however, 
clinical testing was dismissed due to undesirable toxic effects.  
Methodology/Results: The binding landscape of NITD008 in complex with five detrimental 
flaviviruses at the RNA-dependent RNA polymerase active sites were explored. An “all-in-one” 
pharmacophore model was created for the design of small molecules that may inhibit a broad 
spectrum of flaviviruses.  
Conclusions: This pharmacophore model approach serves as a robust cornerstone, thus assisting 
medicinal experts in the composition of multifunctional inhibitors that will eliminate cross-
resistance and toxicity, and enhance patient adherence.  
 
Keywords: 
Flaviviridae, pharmacophore model, Free-binding energy, binding landscape, NITD008, RdRp 
 
Introduction 
Flaviviruses have triggered an abrupt global health concern in the medical field over recent years. 
Flaviviruses come from the family Flaviviridae[1, 2] and are characterized as RNA viruses[3, 4]  
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that are mostly spread by arthropods like mosquitoes and ticks, and are therefore termed arboviruses 
[5, 6]. Examples include the notorious Zika virus (ZIKV) that is transmitted by the Aedes mosquito, 
West Nile virus (WNV), Dengue virus (DENV), Japanese Encephalitis virus( JEV) and Hepatitis 
C virus (HCV) [7–9]. 
 
The lack of antiviral therapies amplifies the expanding threat of these flaviviruses in public health 
[10]. There are currently no established drugs for treating flavivirus diseases [11]. The treatment 
plans are often empiric and border around symptomatic management [12]. Scientists are faced with 
the mammoth task of finding chemical compounds that can not only cure, but also prevent 
transmission of flaviviruses. 
 
Computer-aided drug discovery methods play a major role in the development of therapeutic 
molecules in the medical field [13, 14]. The computational method of designing drugs enables the 
binding properties of a drug to be predicted before it is synthesized thus saving enormous time and 
cost [15–17]. Computational methods will be employed in this study to identify a potential viral 
inhibitor that may aid in the production of a multipurpose antiviral agent against numerous 
flaviviruses. 
 
Despite the efforts scientists have put into the research of flaviviruses, there is an absence of drugs 
that can cure infections caused by Flaviviruses [2, 18]. The dearth of antiviral therapy warrants the 
development of a treatment strategy against flaviviruses. It is therefore imperative that more 
researchers delve into finding antiviral treatments that cure flavivirus infections.  
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In this study, computer-assisted approaches will be used to design a pharmacophore model based 
on the binding landscape and structure activity relationship between potent inhibitor, NITD008 [11, 
19, 20], in complex with five well established flaviviruses being WNV, DENV, JEV, HEPC and 
the ZIKV. This pharmacophore model approach will be able to assist medicinal chemists in the 
design of small molecules against a wide range of flaviviruses, including the re-emerging Zika 
virus, to which there are currently no available FDA approved inhibitors [21–23]. This approach 
may also eliminate common drug design challenges, including cross-resistance and toxicity. 
 
Computational Methods 
The computational approached adapted in this study was outlined in Figure 4.1 
 
Figure 4.1: Computational Methods 
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Measure of Drug Likeliness 
The online software SwissADME was used to determine the physicochemical descriptors and 
define the pharmacokinetic properties and drug-like nature of NITD008. The “Brain Or Intestinal 
Estimated permeation, (BOILED-Egg)” method was utilized as it computes the lipophilicity and 
polarity of small molecules [24].  
 
System Preparation 
The Crystal structures of the RNA-dependent RNA polymerase proteins of WNV (PDB 
code:2HFZ)[25], DENV (PDB code:3VWS)[26], JEV (PDB code:4K6M)[27], HCV (PDB 
code:4WTL)[28] and the ZIKV (PDB code:5WZ3)[29] were retrieved from Protein Data Bank[30]. 
The crystal structures were then super-imposed and all additional ligands were removed using the 
CHIMERA software [31]. 
 
Molecular Docking of Experimental Flaviviruses 
The potent ATP analog, NITD008, was then chosen to dock at each of the flavivirus RdRp sites 
[19, 32, 33]. AutoDock Vina software was used for docking of the compound[34]. The software 
default settings were used to run the procedure. The grid box used to characterize the screening site 
was demonstrated using the AutoDock Vina functionality which is incorporated into Chimera [31]. 
The grid box size and center parameters of the RdRp grid box dimensions were x(18.09, 18), 
y(16.80, 52.9), z(13.75, 12.16). Results from AutoDock Vina were produced in the pdbqt format 
and the optimal geometric conformation having the best binding energy was selected[34] from the 
ViewDock feature and saved in complex with the reference enzymes.  The enzyme and ligand for 
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each system was prepared using Chimera[31] and MMV molecular modeling suites[35] and 
subsequently subjected to molecular dynamic simulations [36]. 
 
Molecular Dynamic Simulations 
The molecular dynamic(MD) simulation was carried out using the GPU version of the PMEMD 
engine provided with the AMBER 14 package [37]. The FF14SB force field which is a component 
of the AMBER package[38] was used to describe the complex. 
 
The Restrained Electrostatic Potential (RESP) and the General AMBER Force Field (GAFF) 
systems were used by ANTECHAMBER[39] to generate the atomic partial charges for the ligands 
[40]. The Leap module of AMBER 14[41] facilitated the  addition of hydrogen atoms to the 
systems, and counter ions (Na+ and Cl- )for neutralization.  
Minimization was done in two stages. The first stage of minimization was carried out with 2000 
steps with a restraint potential of 150 kcal/mol Å2. A full minimization of 1000 steps was then 
carried out by conjugate gradients algorithm with no restrain. 
 
The MD simulation heating was executed gradually from 0 K to 300 K for 50 ps thus allowing the 
system to maintain a fixed number of atoms and fixed volume. The solutes inside the system were 
set with a potential harmonic restraint of 10 kcal/mol Å 2 and collision frequency of 1.0 ps-1. After 
heating, the system was equilibrated for an estimated time of 500 ps with the operating temperature 
being kept constant at 300K. An isobaric-isothermal ensemble (NPT) atmosphere was created by 
keeping constant features such as the number of atoms and pressure. 
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The MD simulation was conducted for 100ns. In each simulation, the SHAKE algorithm played a 
vital role in the constriction of the bonds of hydrogen atoms. Each simulation step took 2 fs and an 
SPFP precision model was used. The simulations coincided with isobaric-isothermal ensemble 
(NPT), with randomized seeding, constant pressure of 1 bar maintained by the Berendsen barostat, 
a pressure-coupling constant of 2 ps, a temperature of 300 K and Langevin thermostat with collision 
frequency of 1.0 ps-1. 
  
Coordinates were saved every 1 ps. The PTRAJ module employed in AMBER14 [37] was used to 
analyze the trajectories. 
 
 
Binding Free energy Calculations 
The Molecular Mechanics/GB Surface Area method (MM/GBSA) [42] was employed for the 
calculation of binding free energies. This was done to estimate the binding affinities of each system. 
Binding free energies were then averaged over 10 000 snapshots extracted from the 100ns 
trajectory. The following equations depict free binding energy (ΔG) which was computed by the 
MM/GBSA method for each molecular species (complex, ligand and receptor): 
∆Gbind = Gcomplex − Greceptor − Gligand                                         (1) 
∆Gbind = Egas + Gsol − TS                                                                  (2) 
Egas = Eint + Evdw + Eele                                                                   (3) 
Gsol = GGB + GSA                                                                                   (4) 
GSA = γSASA                                                                                           (5) 
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The term Egas denotes the gas-phase energy, which consist of the internal energy Eint; Coulomb 
energy Eele, and the van der Waals energies Evdw. The Egas was directly estimated from the 
FF14SB force field terms. Solvation free energy, Gsol, was estimated from the energy contribution 
from the polar states, GGB and non-polar states, G. The non-polar solvation energy, SA. 
 
Pharmacophore Model Creation  
Simulation of the inhibitor, NITD008, occurred at the active site of RdRp, for a period of 100ns. 
This allowed for the bound conformation of the ligand to be created. Per-residue energy 
decomposition analysis [43, 44] was then used to derive the amino acids that greatly participated 
towards the binding of the ligand. The pharmacophoric moieties that significantly interacted with 
the most contributing residues were selected to construct our model. The model was then added to 
ZincPharmer[45] and LigandScout[46] to generate and validate the pharmacophore model. 
Results and Discussion 
Assessment of NITD008’s Drug-likeness 
NITD008 has a plethora of cytotoxic and cardiovascular side effects due to its vasodilatory 
characteristics [32, 33]. This proves to be a challenge when trying to inhibit multiple flaviviruses 
without the manifestation of physiological adverse effects. The online software SwissADME was 
utilized to compute the physicochemical descriptors as well as predict the pharmacokinetic 
properties and drug-like nature of NITD008. SwissADME utilizes the “Brain Or Intestinal 
Estimated permeation, (BOILED-Egg)” method which computes the lipophilicity and polarity of 
small molecules [24].  
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Figure 4.2: Swiss ADME profile of NITD008 
 
Drugs designed for human use should have an ideal balance of pharmacokinetics and safety, as 
well as potency and selectivity. Human oral bioavailability is a paramount pharmacokinetic 
property [47]. Lipophilicity, or LogP, influences a compound’s behavior in biological processes 
pertinent to drug discovery such as solubility, permeability or hepatic clearance. A LogP value of 
between 2 and 3 is more favourable to achieve permeability and first-pass clearance [48]. This 
optimal LogP value is not observed in NITD008 as it falls below the above-stipulated range. It may 
also be worthwhile to mention that although NITD008 is available as an oral drug, the gastro-
intestinal absorption is low. This may decrease its inhibitory activity as a large quantity of the drug 
may be excreted.  
During 2016, influxes of feotal ZIKV-related microcephaly cases were evidenced [6, 49]. Studies 
showed that the ZIKV could pass the blood-brain-barrier (BBB) and infect neuronal cells, thus 
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requiring an inhibitor to cross the BBB [50–52]. NITD008 has however, been predicted not to pass 
the BBB, warranting the need for its optimization. 
Docking of NITD008 with RdRp of Multiple Flaviviruses 
NITD008 is an adenosine analogue that has shown potent antiviral activity against Flaviviruses 
[11, 19, 33]. In this study, NITD008 was docked with five RdRp complexes: DENV, HEPC, JEV, 
WNV and ZIKV. Figure 4.3 illustrates the binding affinity of the five docked complexes. 
 
Molecular docking is extensively utilized bioinformatics tool as a mode to predict the binding 
affinity and orientation of a ligand when it binds to a biological target. After docking, the complexes 
display various alignments of the ligand NITD008 within the active pocket. In as much as scoring 
functions endeavor to replicate experimental binding affinities, most software is not consistent in 
yielding the best prediction. To overcome this challenge, the five docked complexes were subjected 
to 100ns molecular dynamic simulations. This assisted in the validation of the binding affinity and 
allowed for further analysis of the enzyme’s flexibility.  
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Figure 4.3: Binding affinity of NITD008-Flavivirus complex   
System Stability and Thermodynamic binding free energy of the NITD008-RdRp Complexes 
To assure the stability and thus convergence of each system, RMSD was monitored throughout the 
100ns simulation and it was observed that there were no major fluctuations (stable RMSD < 2 Å) 
(Figure 4.4). The ligand also remained stable throughout the trajectory, thus validating the docking 
pose of NITD008 at the active site of the five flaviviruses.  
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Figure 4.4: RMSD plot for the NITD008-flavivirus complex (A) and RMSD plot for the ligand 
NITD008 (B) 
The RMSF plot demonstrated significant fluctuations for DENV, JEV and WNV with JEV being 
furthest from the reference HCV (7.830359Å). ZIKV had a more stable RMSF closer to HCV 
(Figure 4.5). 
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Figure 4.5: RMSF plot for the NITD008-flavivirus complex 
 
The assessment of the free binding energy provided a thorough insight into the total energy 
contributions of each flavivirus complex. Table 4.1 demonstrates the binding energy of each 
complex when bound with NITD008. When compared to the reference complex, HCV, DENV and 
ZIKV shared similar trajectories. The NITD008-DENV complex had a total binding energy of -
25.5361 kcal/mol, which was the closest to that of HCV (-25.2330 kcal/mol). Although ZIKV had 
a total binding energy of -22.2054 kcal/mol, it presented with a more stable RMSD and RMSF, 
exhibiting similar structural characteristics to that of HCV. The NITD008-JEV complex 
demonstrated the lowest binding energy (-18.8802 kcal/mol), thus portraying the least favourable 
 61 
enzyme for NITD008 binding. The RMSD and RMSF of the NITD008-HEPC reference complex 
were stable as expected, presenting minimal residue fluctuation.  
Table 4.1: Summary of free binding energy contributions of the NITD008-flavivirus systems 
 
Energy Contributions of the Highest Interacting Residues at the Active of NITD008 
Based on these results ligand/residue interaction plots were designed to establish the influential 
functional groups of the ligand in each complex (Figure 4.6-4.10). 
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Figure 4.6:  Ligand/residue interaction plot for the NITD008-DENV complex   
 
 
Figure 4.7: Ligand/residue interaction plot for the NITD008-HCV complex   
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Figure 4.8: Ligand/residue interaction plot for the NITD008-JEV complex   
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Figure 4.9: Ligand/residue interaction plot for the NITD008-WNV complex   
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Figure 4.10: Ligand/residue interaction plot for the NITD008-ZIKV complex  
Pharmacophore Model Generation 
Based on the ligand-residue interaction plots as well as the active site residue energy contributions, 
an informative chemical structural map was developed to identify the crucial functional groups 
featured in each flavivirus system. These chemical features were then assembled to form a 
pharmacophore model of the ligand that could pave the road toward the design of one inhibitor to 
treat multiple flaviviruses.  
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Figure 4.11: Common pharmacophoric features from alignment of the flavivirus ligand/residue 
interaction plots, (A) 3D pharmacophore model generated on ZINCPharmer (purple- aromatic 
moiety, gold and white- hydrogen bond donor/acceptor (B) 2D representation of the chemical 
features required for potential flavivirus inhibitors. 
 
A pharmacophore model should not only predict the activity of the training set compounds, but it 
ought to be also capable of predicting the activities of other compounds as active or inactive. We 
validated the generated pharmacophore by docking ATP, for which NITD008 acts as a competitive 
inhibitor, and NITD analogs as true positives. The docking score is illustrated in the table below: 
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Table 4.2: Validation of Pharmacophore 
 
TRUE NEGATIVE 
Compound Name PubChem ID 2D structure Docking score 
ATP 5957 
 
-5.1 
TRUE POSITIVE 
Compound Name PubChem ID 2D structure Docking score 
NITD-203 44633774 
 
-6.4 
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NITD-564 76284487 
 
-8.5 
NITD-609 44469321 
 
-6.0 
NITD-560 127041113 
 
-7.2 
NITD-526 127038059 
 
-8.6 
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These NITD analogs may thus be utilized as a starting point in the design of an “all in one” flavivrus 
inhibitor.  
 
Conclusion  
In the present study, a renowned flaviviral inhibitor (NITD008) was used to analyze the structural 
binding landscape of five flavivirus enzymes. The NITD008-flavivirus systems were subjected to 
100ns MD simulations and the trajectories evaluated using free energy decomposition analysis 
(NITD008-HCV complex as a reference) [19]. Binding affinities were ranked and the results 
demonstrated similar binding interactions to the NITD008-HCV positive control, with the 
NITD008-ZIKV system portraying the greatest similarity. Furthermore, the study prompted us to 
map out a set of structural criteria that could be crucial for further optimization of novel flavivirus 
inhibitors. Chemical features that met the desired criteria were then assembled to form a 
pharmacophore model of the ligand that could pave the road toward the design of one inhibitor to 
treat multiple flaviviruses. This pharmacophore approach may assist medicinal chemists in the 
design of small molecules that may overcome cross-resistance and increase patient adherence.  
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Abstract 
Background. Dengue fever has rapidly manifested into a serious global health concern. 
The emergence of various viral serotypes has prompted the urgent need for innovative drug 
design techniques. Of the viral non-structural enzymes, the NS5 RNA-dependent RNA 
polymerase has been established as a promising target due to its lack of an enzymatic 
counterpart in mammalian cells and its conserved structure amongst all serotypes. The onus 
is now on scientists to probe further into understanding this enzyme and its mechanism of 
action. The field of bioinformatics has evolved greatly over recent decades, with updated 
drug design tools now being publically available. 
Methods. In this study, bioinformatics tools are used to provide a comprehensive sequence 
and structural analysis of the two most prominent serotypes of Dengue RNA-dependent 
RNA polymerase. A list of popular flavivirus inhibitors were also chosen to dock to the 
active site of the enzyme. The best docked compound was then used as a template to 
generate a pharmacophore model that may assist in the design of target-specific Dengue 
virus inhibitors.  
Results. Comparative sequence alignment exhibited similarity between the domains of 
serotype 2 and 3. Sequence analysis revealed highly conserved regions between residues 
“401-441” and “782-809”. Mapping of the active site demonstrated four highly conserved 
residues: lysine, glutamate, serine and tyrosine. Of the active site interacting residues, TYR 
451 was common amongst all docked compounds, indicating its importance in the drug 
design process. Of the 10 docked flavivirus inhibitors, NITD-203 showed the best binding 
affinity to the active site. Further pharmacophore modeling of NITD-203 depicted 
significant pharmacophoric elements that are neccesary for stable binding to the active site. 
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Discussion. This study utilized publically available bioinformatics tools to provide a 
comprehensive framework on Dengue RNA-dependent RNA polymerase. Based on 
docking studies, a pharmacophore model was also designed to unveil the  crucial 
pharmacophoric elements that are required when constructing an efficacious DENV 
inhibitor. We believe that this study will be a cornerstone in paving the road toward the 
design of target-specific inhibitors against DENV RdRp. 
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Introduction 
There are several species under the flavivirus genus that continue to cause detrimental 
effects to infected individuals (King et al., 2007; Holbrook, 2017). One of these species is 
the Dengue virus (DENV), which is the causative agent of DENV fever (John, 2003; 
Guzman & Harris, 2015). The mosquito borne viral infection comes with severe flu-like 
illness when acquired (Guzman et al., 2010; Ross, 2010). 
Studies have shown that approximately 3.9 billion people are prone to  DENV infection 
(Murray, Quam & Wilder-Smith, 2013)(World Health Organization (WHO), 2016). To 
date, there are currently five DENV serotypes in circulation (Dar et al., 2006; Bharaj et al., 
2008; Christenbury et al., 2010; Mustafa et al., 2015; Joob & Wiwanitkita, 2016). Of these 
serotypes, serotype 2 and 3 are the most common (Balmaseda et al., 2006; van Panhuis et 
al., 2010; Fatima et al., 2011). Despite the growing number of strains, the RNA-dependent 
RNA polymerase (RdRp) remains conserved. This RdRp non-structural enzyme also 
remains specific for viral replication and lacks an enzymatic counterpart in mammalian 
cells. This allows researchers to utilize this promising target in the design of DENV 
inhibitors. Although there is constant evolution in this area of research, there still remains 
no approved antiviral drug or vaccine specific to the RdRp region of DENV (Thomas & 
Endy, 2011; Lam, 2013; World Health Organization (WHO), 2016). It is therefore 
imperative to source RdRp-specific inhibitors that aim to put an end to the devastating 
effects of DENV infections. 
The use of information technology has become a critical part of the drug discovery process 
(Hooft, Sander & Vriend, 1997; Huang et al., 2010). Bioinformatics is an emerging science 
that is being exploited to replace the old “hand-crafted” synthesis and testing of new 
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chemical entities approaches (Xu & Hagler, 2002; Chen, 2006). This has been profitable 
to the drug design and discovery industry as it has aided in the circumvention of bottle 
necks which entail time and costs of making new chemical entities in the design process 
(Firdaus Begam & Satheesh Kumar, 2012; Xu & Hagler, 2002). The focal point of 
bioinformatics is to analyze, simulate and manipulate chemical information in order to 
accelerate decision making and reduce expenses in the areas of drug lead identification and 
optimization in the process of drug discovery (Xu & Hagler, 2002; Krasky et al., 2007; Liu 
et al., 2014; Firdaus Begam & Satheesh Kumar, 2012). This study utlizes these bio-
computational techniques to provide comprehensive informational data that will allow for 
the identification or design of inhibitors specific to DENV RdRp. 
Methods 
Bioinformatics tools were used in this study to analyze the structure of DENV RdRp, and 
map out a potential inhibitor specific to the enzyme.  
Crystal Structure Acquisition and Alignment 
The crystal structures of DENV RdRp serotype 2 and 3 were retrieved from the Protein 
Databank (Berman et al., 2000). Serotype 2  and 3 of DENV are represented by PDB codes 
5K5M and 5I3Q, respectively (Lim et al., 2016). Comparitive sequence and structural 
investigations were then carried out using the Chimera software (Pettersen et al., 2004). 
The PDB structures were opened simultaneously in Chimera and superimposed using the 
Match maker function. The sequences were then aligned, and regions of similarity were 
highlighted. It is important to note that following the alignment of the two serotypes, amino 
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acids were renumbered. The correct numbering of the amino acids are depicted to the left 
of the alignment (residues: 266-900).  
Sequence and Structure Analysis 
After aligning the two sequences of DENV, the conserved regions between the two 
serotypes were identified. Important structural features of the RdRp, such as the priming 
loop, were then defined and elaborated on. 
The active site residues were obtained from previous studies (Source et al., 2013; Klema 
et al., 2016). Comparitive analysis between the active site regions of the two serotypes 
were then investigated using the alignment tool available through Chimera.   
Identification and Docking of Popular Flavivirus Inhibitors Specific to the RdRp Region 
Various inhibitors of the RdRp region of DENV were selected from literature based on 
their compelling inhibitory characteristics (Garcia et al., 2017). The best 10 compounds 
were then docked to the active site of DENV RdRp using the Autodock plugin of Chimera 
(Morris et al., 2009). Of each of the docked complexes, the RdRp residues interacting with 
the compounds were identified. After evaluating the binding affinities, the inhibitor with 
the best docked pose was used as a modeltodemonstrate the pharmacophoric elements that 
are required when designing an efficient lead compound. Based on active site residue 
interactions with functional groups of NITD-203, the Ligandscout software (Wolber & 
Langer, 2005) was used to show these vital pharmacophoric elements.  
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Results and Discussion 
Assembly of Structural and Non-structural DENV proteins  
Dengue is an enveloped flavivirus, which consists of a positive-sense RNA virus 
approximately 11kb in size (Miller et al., 2008). This RNA encodes 3 structural proteins 
that form the components of the virion: the capsid (C), precursor membrane (prM) and the 
envelope (E). In addition to this assembly, there are seven non-structural (NS) proteins 
namely NS1, NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5 (Kuhn et al., 2002; Shu et 
al., 2004; Perera & Kuhn, 2008; Sahili & Lescar, 2017). Of the structural and non-structural 
proteins, crystal structures are available for the capsid (1R6R), envelope (4UTC), NS1 
(4O6B), NS2 (2FOM), NS3 (2VBC) and NS5 (1L9K, 5K5M) (Figure 1).    
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Figure 5.1: Dengue polyprotein demonstrating available crystal structures (PDB codes: 
1R6R, 4UTC, 4O6B, 2FOM, 2VBC, 1L9K, 5K5M) (Prepared by Authors). 
The NS5 is the largest non-structural protein and comprises of the methyltransferase and 
RNA-dependent RNA polymerase (RdRp) (Zhao et al., 2015; Klema et al., 2016). In the 
study, bioinformatics tools were utilized to explore the unique characteristics of the RdRp 
enzyme. The RdRp plays a significant role in RNA synthesis by catalyzing the replication 
of RNA synthesis via a two-step mechanism, thus validating it as a target for antiviral 
therapy (Ferron et al., 2005; Paschal et al., 2008). 
 
Sequence and Structural analysis of DENV RdRp 
The RdRp of DENV is located on the C terminus of the NS5 protein from residue number 
266-900 (Appleby et al., 2005; Yap et al., 2007; Perera & Kuhn, 2008; Klema et al., 2016).  
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Figure 5.2: The overall structure and sequence analysis of the RdRp enzyme of DENV 
serotype 2 and 3. The green colour represents the finger domain (273-315,416-496 and 
543-600); the yellow represents the palm domain (497-542 and 601-705) and the blue 
represents the thumb domain (706-900). The priming loop found in the thumb domain is 
represented by the red colour (782-809). 
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The highlighted regions of the sequence represent the three domains of the RdRp region 
(Lu & Gong, 2017). The green highlight represents the finger region, the yellow represents 
the palm and the blue represents the thumb (Yap et al., 2007; Klema et al., 2016) (Figure 
2). A general resemblance of amino acids was noted between DENV serotypes 2 and 3 
(King et al., 2007; Wu, Liu & Gong, 2015; Silva et al., 2008; Zhao et al., 2012; 
Manakkadan et al., 2013; Pitcher et al., 2015). Regions of maximum resemblance lie 
between 401 and 441 within the palm region. However, significant variations are 
prominent within the finger region. This is due to genetic alterations that have caused the 
DENV virus to mutate (Holmes & Burch, 2000; Holmes & Twiddy, 2003; Hellenthal & 
Stephens, 2006). This genetic variation is caused by error-prone RdRp, which lacks 
proofreading activity and generates approximately one mutation per round of genome 
replication (Elena SF, 2005; Sessions et al., 2015). Genetic recombination is also known 
to cause intra-serotype genetic variation in DENV (Uzcategui et al., 2001; Craig et al., 
2003; Holmes & Twiddy, 2003; Perez-Ramirez et al., 2009). 
The architecture of the DENV RdRp adopts a canonical right-hand conformation 
comprising of a finger, palm and thumb domain surrounding its active site (Lu & Gong, 
2017). This applies to most polymerases (Ago et al., 1999; Duan et al., 2017). Dengue, 
however, has a nuclear localized structure (NLS) that plays a major role in its structural 
formation (Yap et al., 2007; Zhao et al., 2015). The NLS signatures are distributed between 
the finger and thumb domains from residues 316-415. This region forms the hotspot for 
interactions with other viral and host proteins (Johansson et al., 2001; Zou et al., 2011; 
Brooks et al., 2002). Alterations within the NLS region lead to structural destabilization 
(Pryor et al., 2007; Yap et al., 2007; Malet et al., 2007).  
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Finger domain 
The finger domain is divided into two subdomains. The first strand is a beta-rich-strand (β) 
subdomain and the fingers found in this strand are termed beta-fingers (Ago et al., 1999). 
The other strand is rich in alpha-helices(α) and therefore the fingers found in this region 
are alpha-fingers. In addition, the finger region has four flexible loops, β1-α2, α3-α4, α6-
α7 and α7- α8. Overall, the residues in the finger region are from 273-600 (Egloff et al., 
2002; Galiano et al., 2016; Duan et al., 2017). The finger domain is located at the top of 
the RdRp enzyme and appears to be more mobile than the other two domains (Poch et al., 
1989; Ng, Arnold & Cameron, 2008; Zou et al., 2011). 
 
Palm domain  
The palm domain is a catalytic domain that encompasses a highly conserved folding motif 
(Malet et al., 2007; Yap et al., 2007). The palm consists of two antiparallel β-strands, β4 
and β5, and is surrounded by eight helices which are α11-α13 and α16-α20.  Of the six 
conserved sequence motifs located in the palm region, four are specifically involved in 
nucleotide triphosphate (NTP) binding and catalysis (Bruenn, 1991; D’Haeseleer, 2006; 
Ferrer-Orta et al., 2006; Doolittle & Gomez, 2011; Asnet Mary, Paramasivan & 
Shenbagarathai, 2015; Galiano et al., 2016; Duan et al., 2017). 
Thumb domain 
The thumb domain stabilizes the C-terminal end of the RdRp, (Midgley et al., 2012) and 
is composed of residues 706-900 on the β6-α23 strands(Yap et al., 2007; Galiano et al., 
2016). Of the known polymerase structures, the DENV thumb region shows the most 
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unique structural variation (Paschal et al., 2008; Cramer & Arnold, 2009). The thumb 
domain contains a conserved sequence motif that forms an antiparallel β-sheet wedged 
between the palm domain and several α-helices of the thumb domain (Ng, Arnold & 
Cameron, 2008; Pierson & Diamond, 2012). This unique structure contributes to the 
shaping of the RNA template tunnel (Benarroch et al., 2004; Yap et al., 2007; Welsch et 
al., 2009).  
 
Figure 5.3: A closer look into the priming loop region highlighted in red in the DENV 
RdRp region.  
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Priming loop 
A second loop consisting of amino acids 782-809 forms the priming loop, which partially 
blocks the active site (Figure 3). The priming loop plays a key role in initiating the 
enzymatic activity of the RdRp (Gebhard, Filomatori & Gamarnik, 2011; Selisko et al., 
2012; te Velthuis et al., 2016). Internal interactions, including hydrogen bonds, act to 
stabilize the priming loop, thus maintaining the orientation of the protein structure (Ng, 
Arnold & Cameron, 2008; Campagnola et al., 2015). The priming loop is also known as 
the G-loop because it corresponds to motif G in primer-dependant RdRps. The 
characteristic “hairpin” structure of the loop is partially disordered in flavivirus RdRp 
structures, suggesting conformational flexibility (Malet et al., 2008; Source et al., 2013). 
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Comparative Mapping of DENV RdRp Active Site 
 
Figure 5.4: The active site region and sequence analysis of DENV. 
The RdRp active site is characterized by a conserved region comprising of a glycine-
aspartate core section located in the palm domain (Jablonski, Luo & Morrow, 1991; 
Routhier & Bruenn, 1998; Wu, Liu & Gong, 2015). The active site of DENV is made up 
of hydrophobic residues 311-317 and 451-457 (Source et al., 2013; Klema et al., 2016), 
which are located above the palm domain (Ago et al., 1999; Lesburg et al., 1999) (Figure 
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4). One of the unique characteristics of the active site is that it is located at the 
intersections of two tunnels.  The finger and thumb domain form the first tunnel, which 
is responsible for coordinating the single-stranded RNA, while the second tunnel 
coordinates the nascent double-stranded RNA (Yap et al., 2007).  
Mutations on the active site have contributed to challenges in finding inhibitors for DENV 
(Mateo, Nagamine & Kirkegaard, 2015), thus analysis of the active site will enable 
researchers to find broad spectrum inhibitors against both serotypes of DENV.   
Seven catalytic motifs, A to G, have been identified for DENV RdRp. These motifs 
contribute to the sequence and structural conservation of the RdRp active site. Motifs A 
and C contain two aspartic acid residues that are universally conserved amongst 
Flaviviruses. Motif B has a highly conserved RdRp-specific serine-glycine sequence, 
which is replaced by threonine in drug-resistant strains (Perera & Kuhn, 2008; Klema et 
al., 2016; Yap et al., 2007). The glycine adjacent to motif B provides the backbone 
flexibility needed for conformational switches around the adjacent serine. The sequence is 
also vital for allowing large-scale conformational changes of the motif B loop. Motif D 
does not have conserved residues, however, it contains a lysine residue that has been shown 
to contribute in catalysis. Motif E and G do not contain conserved residues, but contribute 
to the composition of the active site of the RdRp (Yap et al., 2007; Lim et al., 2016; Zhao 
et al., 2012). 
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Conquering Targeted Therapy with Popular Drugs 
Studies have identified multiple general flavivirus RdRp inhibitors, however, there are 
currently no FDA approved drugs that are specific to all serotypes of the RdRp region of 
DENV. The development of an antiviral therapy for DENV is further complicated by the 
fact that protection against one serotype leads to increased vulnerability against the other 
serotypes (Heinz & Stiasny, 2012). This study therefore seeks to fill the gap between the 
increase in DENV case reports and absence of antivirals. Over the years, inhibitors that 
have shown potential antiviral activity come with multiple challenges including elevated 
toxicity levels. Scientists are therefore still battling to find an inhibitor that is potent, 
efficacious and non-toxic for the treatment of DENV (Galiano et al., 2016; García, Padilla 
& Castaño, 2017; Ramharack & Soliman, 2017). 
In this study, various potent inhibitors of the RdRp region of DENV were assessed. Based 
on a study by García et al., 2017, experimental compounds that demonstrated compelling 
inhibition of DENV were chosen and docked into the active site of DENV RdRp. The ten 
best docked poses were reported in Table 1. The RdRp residues interacting with the docked 
compounds were identified, thus adding to the requirements needed when designing a 
possible inhibitor of DENV. Of these residues, TYR 451 was found in nine out of ten of 
the complexes, indicating its importance as an interacting residue for both serotypes. 
Various studies have proved NITD008 to be a potent flavivirus inhibitor (Yin et al., 2009; 
Shan et al., 2013; Deng et al., 2014, 2016). The binding affinities, however, showed that 
NITD-203 had the best docking score (-6.4 kcal/mol). The NITD-203 compound is an 
adenosine analog that has been shown to have potent competitive inhibition of adenosine 
triphosphate (ATP) at the active site of RdRp. It is, however, important to note that one of 
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the most common adverse effect of nucleoside compounds such as NITD-203 is 
mitochondrial toxicity (Garcia et al., 2017). This dismisses the compound’s progression to 
FDA approval. Nonetheless, NITD-203 may still be utilized in the development of DENV 
antiviral therapy. 
Table 5.1: Popular flavivirus inhibitors bound to DENV RdRp (Adapted from (García, 
Padilla & Castaño, 2017)). 
Compound Mechanism of Action 
Binding 
Energy 
(kcal/mol) 
Pose 
Amino acid 
residues 
NITD008 
Inhibitor of all 4 
DENV serotypes (Lim 
et al., 2013; Caillet-
Saguy et al., 2014a; Lo 
et al., 2016). 
-5.5 
 PHE 127   
ARG 210    
LYS 130     
VAL 131    
ASN 134    
ALA 135    
GLN 332   
TYR335     
TYR 336 
 
 
Balapiravir 
A cytidine nucleoside 
that is a domain RdRp 
inhibitor (Lim et al., 
2013). 
-6.1 
 TYR451 
ASN452 
VAL577 
ARG594 
VAL576  
Lycorine 
A potent flavivirus 
inhibitor in cell culture 
through suppression of 
viral RNA replication 
(Zou et al., 2009; Lim 
et al., 2013). 
-5.8 
 TRP 474    
TRP 477      
TYR 451      
SER 470    
VAL 579     
LYS 578    
MET 589 
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Ribavirin 
Significant in vitro 
activity against 
flaviviruses (Gilbert et 
al., 1985; Feld et al., 
2017). 
-5.0 
 TYR 451     
ASN 452     
GLN 580    
VAL 579     
VAL 310      
ILE 473  
7-deaza-
2’methyladeno
sine 
Potent ZIKV inhibitor 
that reduces viremia 
(Zmurko et al., 2016) 
-5.5 
 ILE 283      
GLU 286      
ILE 473     
MET 453    
MET 589    
TYR 451 
3’Dgtp 
GTP analogue that 
inhibits DENV-2 RdRp 
but has a low IC50 
value (Malet et al., 
2008) 
-5.0 
 MET 589    
VAL 579     
LYS 578    
ASN 452    
TYR 451    
VAL 310    
TYR 308 
2’O-metil GTP 
Showed low IC in vitro 
DENV-2 (Malet et al., 
2008). 
-5.3 
 THR 343    
THR 313   
TYR 451    
TRP 477    
GLY 349    
ASN 452 
NITD 203 
Inhibitor of all 4 
DENV serotypes 
(Caillet-Saguy et al., 
2014b). 
-6.4 
 VAL 358    
GLY 599    
TYR 451      
ILE 591      
GLY 601    
SER 600            
LYS 578     
VAL 538 
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Favipiravir 
A pyrazine-substitute 
compound that has 
shown to inhibit 
flavivirus mortality in 
rodents (Furuta et al., 
2009). 
-4.0 
 
ASN 452    
TYR 451    
VAL 579     
LYS 578  
Ivermectin 
Pretreatment of 
ivermectin with N-(-4-
hydroxyphenyl) 
inhibits the nuclear 
localization of NS5 
(Tay et al., 2013). 
-5.3 
 ASN 452    
LYS 578    
TYR 451   
VAL 579     
VAL 310    
MET 453 
 
Based on the “prodrug” characteristics of NITD-203, it was chosen as a model to identify 
specific pharmacophoric elements that are required when designing an efficient inhibitor 
of all five serotypes. Pharmacophore modeling is a pivotal tool exploited in rational drug 
design, providing crucial insights into the nature of the interactions between a drug target 
and ligand. It involves the concept of "privileged structures", which are molecular 
frameworks capable of providing useful ligands for more than one type of protein. 
Pharmacophore models are vital in drug design as they act as templates for screening 
compounds that have similar structural and chemical features. These ligands could then be 
used as lead compounds against various diseases (Wolber & Langer, 2005; Gao et al., 2010; 
Qing et al., 2014).  
In this study, we have therefore utilized this pharmacophoric approach to design a model 
based on NITD-203 that may be used as a stepping stone toward efficient DENV inhibitors. 
The Ligandscout (Wolber & Langer, 2005) software was used to demonstrate the vital 
pharmacophoric elements required when designing a DENV RdRp inhibitor. These 
chemical features were based on active site residue interactions with functional groups of 
NITD-203 (Figure 5).  
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Figure 5.5: Significant pharmacophoric elements of NITD-203 for the design of target-
specific inhibitors of DENV RdRp (HBA/D- Hydrogen bond acceptor/donor, H-
Hydrophobic, AR- Aromatic). 
 
Based on the pharmacophore model identified in Figure 5, chemical features such as 
hydrogen bond donors/acceptors as well as aromatic rings are crucial elements that are 
required in constructing an efficacious DENV inhibitor. We believe that this study will be 
a cornerstone in paving the road toward the design of target-specific inhibitors against 
DENV RdRp.  
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Conclusions  
Dengue is an established flavivirus that is causing distress in the lives of many. The 
development of an antiviral against DENV is further complicated by its manifestation into 
various serotypes. This augments the need for innovative research methods in DENV drug 
design. The bioinformatics techniques discussed in this paper will aid in the identification 
of potential RdRp inhibitors, thus mitigating the effects of DENV in the lives of 
compromised individuals, as well as prevent the transmission of DENV on a global scale. 
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CHAPTER 6 
6.1 Conclusion 
The present study sought to investigate a notorious flavivirus that has been in circulation for over 30 years. 
Over the last few decades, DENV has re-emerged in various serotypes and is causing mayhem in the lives of 
many 1,2. Dengue is dreaded for the severe fever it causes in its advanced stage. Dengue has the reputation of 
what is known as Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), a leading cause of 
death in children in some Asian countries 3. The vertical transmission of Dengue is also a cause of concern 
as it has teratogenic effects 4. Its rapid spread has made it arduous to restrain and eradicate. 
 
Attempts have been made to design vaccines and small drug molecules as potential inhibitors against DENV. 
The virus however is resilient, and exists in 5 serotypes with numerous strains under them, thwarting the 
efforts of researchers to curb its spread. This prompted us to design a study that would address the above 
challenges by use of CADD tools, which elaborated on the design of target-specific inhibitors of DENV from 
an atomistic perspective.  
 
In this study, there were two aims, which were to design an “All-in-one” pharmacophoric architecture for the 
discovery of potential broad spectrum anti-flavivirus drugs, and to provide a comprehensive cheminformatics 
based review for the discovery of DENV serotypes 2 and 3 inhibitors. 
 
A renowned flaviviral inhibitor (NITD008) was used to analyze the structural binding landscape of five 
flavivirus enzymes. The NITD008-flavivirus systems were subjected to 100ns MD simulations and the 
trajectories evaluated using free energy decomposition analysis (NITD008-HCV complex as a reference). 
Binding affinities were ranked and the results demonstrated similar binding interactions to the NITD008-
HCV positive control, with the NITD008-ZIKV system portraying the greatest similarity. Furthermore, the 
study prompted us to map out a set of structural criteria that could be crucial for further optimization of novel 
flavivirus inhibitors. Chemical features that met the desired criteria were then assembled to form a 
pharmacophore model of the ligand that could pave the road toward the design of one inhibitor to treat 
multiple flaviviruses. This pharmacophore approach may assist medicinal chemists in the design of small 
molecules that may overcome cross-resistance and increase patient adherence.  
 
The development of an antiviral against DENV is further complicated by its manifestation into five serotypes. 
This augmented the need for innovative research methods in DENV drug design. The cheminformatics and 
bioinformatics discussed herein resulted in a comprehensive and comparative review of the two most 
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prominent serotypes of DENV. The analysis of popular flavivirus inhibitors laid the foundation to identify a 
molecular framework that will aid in the identification of potential DENV inhibitors. We believe that these 
findings will aid in mitigating the effects of the DENV in the lives of the compromised individuals, as well 
as prevent the transmission of DENV from patients to healthy individuals. 
Overall, this study has provided valuable insights into the design and development of DENV inhibitors 
through molecular modeling and CADD.  
 
6.2 Future Perspectives 
The potential inhibitors of the study have presented promising protein-ligand interactions and binding 
energies and therefore maybe utilized as the lead compounds. Prospective biological experimentation is 
however mandatory for the testing of these compounds in order to verify these in silico studies.  
 
The ramifications of DENV infection have led to a multitude of potential small molecule inhibitors and 
vaccines that are currently in clinical trials. The virus nonetheless has other challenging defense mechanisms 
that may render most drugs and vaccines ineffective. The co-existence of 5 serotypes has regressed efforts 
made by researchers as DENV is ever mutating. 
 
With regard to this investigative study, a purely computational perspective was used. To further the DENV 
drug design research toward targeted therapy, the design of an experiment is warranted to analyze the efficacy 
of the pharmacophores mentioned above. Screened inhibitors based on the pharmacophores designed can be 
procured and tested through rational drug design to find lead compounds that are effective against DENV. 
As far we know, this is the first study that has mapped out a path for small molecules that are target-specific 
to the DENV RdRp.  
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